XML 75 R48.htm IDEA: XBRL DOCUMENT
v3.25.4

Segment Information (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2025
Segment Reporting [Abstract] |
Schedule of Segment Reporting Information, by Segment | The following table presents summary results of the Company’s reportable segments and a reconciliation of total segment operating loss to consolidated loss before income taxes (in thousands):
| Year Ended December 31,
| 2025 |  | 2024 |  | 2023
Cell Engineering |  |  |  |  |
Revenue | $ | 132,746 |  |  | $ | 173,972 |  |  | $ | 143,531 |
Costs and operating expenses: |  |  |  |  |
Cost of other revenue | 13,203 |  |  | 5,999 |  |  | — |
Research and development | 158,541 |  |  | 271,512 |  |  | 335,943 |
General and administrative | 56,532 |  |  | 115,028 |  |  | 171,210 |
Cell Engineering operating loss | (95,530) |  |  | (218,567) |  |  | (363,622) |
Biosecurity |  |  |  |  |
Service revenue | 37,409 |  |  | 53,071 |  |  | 78,975 |
Product revenue | — |  |  | — |  |  | 28,949 |
Costs and operating expense: |  |  |  |  |
Cost of Biosecurity service revenue | 28,897 |  |  | 38,549 |  |  | 46,524 |
Cost of Biosecurity product revenue | — |  |  | — |  |  | 7,481 |
Research and development | — |  |  | 771 |  |  | 1,599 |
General and administrative | 27,443 |  |  | 44,370 |  |  | 55,514 |
Biosecurity operating (loss) income | (18,931) |  |  | (30,619) |  |  | (3,194) |
Total segment operating loss | (114,461) |  |  | (249,186) |  |  | (366,816) |
Reconciling items to reconcile total segment operating loss to loss before income taxes:
Stock-based compensation (1) | 82,704 |  |  | 115,299 |  |  | 234,908 |
Impairment expense (2) | — |  |  | 53,654 |  |  | 121,404 |
Depreciation and amortization | 58,990 |  |  | 63,020 |  |  | 70,507 |
Restructuring charges (3) | 11,398 |  |  | 24,172 |  |  | — |
Carrying cost of excess space (net of sublease income) (4) | 53,723 |  |  | 25,986 |  |  | — |
Merger and acquisition related expenses (5) | (5,998) |  |  | 4,417 |  |  | 61,188 |
Acquired in-process research and development | — |  |  | 19,849 |  |  | 9,582 |
Other (income) expense, net (6) | (1,678) |  |  | (8,075) |  |  | 28,535 |
Loss before income taxes | $ | (313,600) |  |  | $ | (547,508) |  |  | $ | (892,940) |
(1)Includes $1.2 million, $3.0 million, and $5.0 million in related employer payroll taxes for the years ended December 31, 2025, 2024, and 2023, respectively. (2)For 2024, includes $47.9 million related to goodwill impairment and $5.8 million related to lab equipment. For 2023, includes a $25.2 million impairment loss on lab equipment and a $96.2 million impairment loss on lease assets associated with an exited Zymergen leased facility. (3)See Note 3, Restructuring, for composition of costs. (4)The carrying cost of excess space includes base rent, common area maintenance charges, and real estate taxes associated with facilities the Company is not occupying, net of any sublease income from these spaces. (5)Represents transaction and integration costs directly related to mergers and acquisitions, including: (i) due diligence, legal, consulting and accounting fees associated with acquisitions, (ii) post-acquisition employee retention bonuses and severance payments, (iii) the fair value adjustments to contingent consideration liabilities resulting from acquisitions, and (iv) costs associated with the Zymergen Bankruptcy, as well as securities litigation costs, net of insurance recovery. (6)Includes interest income, interest expense, loss on investments, losses/gains on deconsolidation of subsidiaries, changes in fair value of certain assets and liabilities, and other gains or losses.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration